AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus a leader in precision pathology have entered into an agreement to conduct a pilot study applying the AIxMed’s AI algorithm to test a workflow solution for urine cytology.
Providers of digital cytology scanning and AI software to create workflow solution SANTA CLARA, Calif. , April 18, 2024 /PRNewswire/ -- AIxMed, innovators and providers of an AI-powered computational platform for cytology applications, and CorePlus a leader in precision pathology have entered into an agreement to conduct a pilot study applying the AIxMed's AI algorithm to test a workflow solution for urine cytology. "...an AI-powered computational platform will save time, improve accuracy, and greatly aid research..."
AIxMed's experience in cytology software and analysis, combined with CorePlus' experience in integrating digital and AI solutions into their day-to-day pathology workflow will come together to provide an end-to-end solution for research-use only urine cytology analysis. "Both AIxMed and CorePlus have demonstrated our commitment to enhancing urine cytology workflow efficiencies utilizing the tools of digital cytology, so joining forces to demonstrate a new digital urine cytology platform together is a natural fit," said Samuel Chen, CEO of AIxMed. Due to the shortage of cytologists and the manual nature of cell characterization, cytology needs new tools to improve workflow and provide quantitative and qualitative information. AI-powered computational tools have the potential to deliver these insights and allow a more efficient and precise process with the existing workforce. "Being able to rapidly image slides with our in-house scanner for cytology, and then characterize cells with an AI-powered computational platform will save time, improve accuracy, and greatly aid research in the battle against bladder cancer," said Mariano de Socarraz, Founder and CEO of CorePlus. About AIxMed About CorePlus
SOURCE AIxMed, Inc. |